Genmab — Oktober 2022

[Helge_LarsenPI-redaktør]

Godmorgen

[Stroka]

God morgen.

[ProinvestorNEWS]

Godmorgen.

[ProinvestorNEWS]

Asien: Ferietyndt let faldende marked trods plusser i Tokyo https://www.proinvestor.com/investornyt/885602/asien-ferietyndt-let-faldende-marked-trods-plusser-i-tokyo

[ProinvestorNEWS]

Mandagens danske avisuddrag med retssag, recession og brudte løfter https://www.proinvestor.com/investornyt/885605/mandagens-danske-avisuddrag-med-retssag-recession-og-brudte-lofter

[ProinvestorNEWS]

Aktier/tendens: Vestas i fokus før ventet rød start på fjerde kvartal https://www.proinvestor.com/investornyt/885620/aktier-tendens-vestas-i-fokus-for-ventet-rod-start-pa-fjerde-kvartal

[E_L]

Congress | #SOHO22 Alex Herrera from
@cityofhope
presents updated results from a phase II study where camidanlumab tesirine demonstrated an ORR of 70.1%, median DOR of 13.7 months and median PFS of 9.1 months in patients with R/R CHL https://twitter.com/lymphomahub/status/1575986164598964224

[E_L]

ADC Offers Promising Results in Relapsed or Refractory... https://www.medpagetoday.com/meetingcoverage/soho/101011

[E_L]

Teclistamab Shows Promise for People with Heavily Pretreated Multiple Myeloma https://www.cancer.gov/news-events/cancer-currents-blog/2022/tecvayli-multiple-myeloma

[E_L]

Oxford BioTherapeutics enters into Commercial License Agreement with Genmab https://www.prnewswire.com/news-releases/oxford-biotherapeutics-enters-into-commercial-license-agreement-with-genmab-301638067.html

[Stroka]

Dem som købte den store aktiepost med rabat i sidste uge må være glade i dag.

[Solsen]

Genmab i top i dag

[Helge_LarsenPI-redaktør]

Hvorfor egenligt det?

[gdn55]

Fordi den er meget mere værd, måske.
Hvad ved jeg

[E_L]

interest rates. bunds go up, genmab goes up.

[Helge_LarsenPI-redaktør]

Det er vi enige om gdn55.

[Legolas23]

Enten kommer nyheden efter luk eller også er det fordi Genmab er eksponeret op mod dollaren.

[bikube]

De links E L har smidt op, er da heller ikke værdiløse. Når de gode nyheder kommer i stimer, så må det da virke lidt.

[gentogen]

Der var faktisk en lille nyhed i eftermiddags: Oxford, UK and San Jose, California, 3 October 2022 - Oxford BioTherapeutics (OBT), a clinical
stage oncology company with a pipeline of immuno-oncology (IO) and antibody drug conjugate
(ADC)-based therapies, today announced that global oncology leader, Genmab has licensed a
novel antibody related to one of OBT’s IO programs.

[gentogen]

http://www.oxfordbiotherapeutics.com/uploads/9/5/4/2/9542591/2022_10_03_obt_genmab_license_agreement_pr_final.pdf